Roche's Gazyva/Gazyvaro Lands Priority Review From US FDA in Nephropathy
() -- Roche's (RO.SW) supplemental biologics license application for Gazyva/Gazyvaro received priority review from the US Food and Drug Administration for the treatment of primary membranous nephropathy, or pMN, a chronic autoimmune disease with no approved therapies in the US or Europe. The priority review is based on